Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Ovarian Neoplasms 16Lung Neoplasms 15Breast Neoplasms 14Endometrial Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 12Fallopian Tube Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Neoplasm Metastasis 8Triple Negative Breast Neoplasms 5Esophageal Neoplasms 5Adenocarcinoma Of Esophagus 5Stomach Neoplasms 4Neoplasms 4Melanoma 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 3Carcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Peritoneal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Brenner Tumor 2Anatomic Stage I Breast Cancer AJCC v8 2Advanced Solid Tumour 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Adenocarcinoma 2Uterine Neoplasms 1

Interventions

Oxaliplatin 3Leucovorin 3Fluorouracil 3Capecitabine 3zolbetuximab 2trastuzumab deruxtecan 2pembrolizumab 2Ramucirumab 2Paclitaxel 2repotrectinib 1lenvatinib 1fludarabine 1enzalutamide 1durvalumab 1darolutamide 1aldesleukin 1Vinorelbine 1Radiosurgery 1Radiation 1Prednisone 1Prednisolone 1Positron-Emission Tomography 1Pemetrexed 1PF06821497 1Nivolumab 1Negative-Pressure Wound Therapy 1Microscopy, Confocal 1MORAb-202 1Irinotecan 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma × Paclitaxel × 30 days × Clear all
NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Recruiting
398 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Daiichi Sankyo

Phase 3 Active not recruiting
490 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡